π£ VC round data is live. Check it out!
- Public Comps
- Polynovo
Polynovo Valuation Multiples
Discover revenue and EBITDA valuation multiples for Polynovo and similar public comparables like Tactile Medical, Japan Lifeline, NeuroPace, Cerus and more.
Polynovo Overview
About Polynovo
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avitaβs RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Founded
1998
HQ

Employees
301
Website
Financials (LTM)
EV
$553M
Valuation Multiples
Start free trialPolynovo Financials
Polynovo reported last 12-month revenue of $105M and EBITDA of $8M.
In the same LTM period, Polynovo generated $97M in gross profit, $8M in EBITDA, and $5M in net income.
Revenue (LTM)
Polynovo P&L
In the most recent fiscal year, Polynovo reported revenue of $91M and EBITDA of $7M.
Polynovo is profitable as of last fiscal year, with gross margin of 96%, EBITDA margin of 8%, and net margin of 10%.
Financial data powered by Morningstar, Inc.
Polynovo Stock Performance
Polynovo has current market cap of $561M, and enterprise value of $553M.
Market Cap Evolution
Polynovo's stock price is $0.81.
Polynovo share price increased by 13.8% in the last 30 days, and decreased by 12.9% in the last year.
Polynovo has an EPS (earnings per share) of $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $553M | $561M | -0.0% | 13.8% | 17.2% | -12.9% | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPolynovo Valuation Multiples
Polynovo trades at 5.3x EV/Revenue multiple, and 67.9x EV/EBITDA.
EV / Revenue (LTM)
Polynovo Financial Valuation Multiples
As of May 23, 2026, Polynovo has market cap of $561M and EV of $553M.
Polynovo has a P/E ratio of 122.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Polynovo Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Polynovo Margins & Growth Rates
Polynovo grew revenue by 18% and EBITDA by 10% in the last fiscal year.
In the most recent fiscal year, Polynovo reported gross margin of 96%, EBITDA margin of 8%, and net margin of 10%.
Polynovo Margins
Polynovo Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Polynovo Operational KPIs
Polynovo's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Polynovo's Rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Polynovo's Rule of X is 62% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Polynovo Competitors
Polynovo competitors include Tactile Medical, Japan Lifeline, NeuroPace, Cerus, MiMedx Group, Wellgistics Health, Sofwave Medical, Tess Holdings Co, Beta Bionics and Mesa Laboratories.
Most Polynovo public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.5x | 1.4x | 10.9x | 10.4x | |||
| 1.4x | 1.4x | 5.9x | 5.7x | |||
| 5.9x | 5.9x | (118.1x) | (91.1x) | |||
| 2.4x | 2.3x | 58.8x | 41.5x | |||
| 1.0x | 1.1x | 3.8x | 5.8x | |||
| 24.0x | β | (6.0x) | β | |||
| 5.7x | β | 65.3x | β | |||
| 4.0x | 3.3x | 27.3x | β | |||
This data is available for Pro users. Sign up to see all Polynovo competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Polynovo
| When was Polynovo founded? | Polynovo was founded in 1998. |
| Where is Polynovo headquartered? | Polynovo is headquartered in Australia. |
| How many employees does Polynovo have? | As of today, Polynovo has over 301 employees. |
| Who is the CEO of Polynovo? | Polynovo's CEO is Robyn Elliott. |
| Is Polynovo publicly listed? | Yes, Polynovo is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Polynovo? | Polynovo trades under PNV ticker. |
| When did Polynovo go public? | Polynovo went public in 1998. |
| Who are competitors of Polynovo? | Polynovo main competitors include Tactile Medical, Japan Lifeline, NeuroPace, Cerus, MiMedx Group, Wellgistics Health, Sofwave Medical, Tess Holdings Co, Beta Bionics, Mesa Laboratories. |
| What is the current market cap of Polynovo? | Polynovo's current market cap is $561M. |
| What is the current revenue of Polynovo? | Polynovo's last 12 months revenue is $105M. |
| What is the current revenue growth of Polynovo? | Polynovo revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Polynovo? | Current revenue multiple of Polynovo is 5.3x. |
| Is Polynovo profitable? | Yes, Polynovo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Polynovo? | Polynovo's last 12 months EBITDA is $8M. |
| What is Polynovo's EBITDA margin? | Polynovo's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Polynovo? | Current EBITDA multiple of Polynovo is 67.9x. |
| What is the current FCF of Polynovo? | Polynovo's last 12 months FCF is ($1M). |
| What is Polynovo's FCF margin? | Polynovo's last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of Polynovo? | Current FCF multiple of Polynovo is (370.4x). |
| How many companies Polynovo has acquired to date? | Polynovo hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Polynovo has invested to date? | Polynovo hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Polynovo
Lists including Polynovo
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.